Belite Bio (BLTE) Income towards Parent Company (2022 - 2026)
Belite Bio (BLTE) posted quarterly Income towards Parent Company of -$26.9 million for Q1 2026, down 88.68% year-over-year from -$238.0 million in Q1 2025, and up 99.89% quarter-over-quarter from -$25.3 billion in Q4 2025.
Belite Bio (BLTE) Income towards Parent Company (2022 - 2026) Analysis & Trends
Belite Bio's Income towards Parent Company history runs 5 years deep, the most recent figure standing at -$26.9 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 88.68% year-over-year to -$26.9 million; the TTM figure through Mar 2026 stood at -$63.4 billion (down 124.04% YoY), while the FY2025 annual figure was -$77.5 million, down 131.85% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$26.9 million, up from -$25.3 billion in the prior quarter.
- The five-year high for Income towards Parent Company was -$6.8 million in Q4 2022, with the low at -$25.3 billion in Q4 2025.
- The 5-year median for Income towards Parent Company is -$6.9 billion (2023), against an average of -$7.4 billion.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company tumbled 144392.13% in 2024, then soared 99.82% in 2025.
- Belite Bio's Income towards Parent Company stood at -$6.8 million in 2022, then dropped by 3.05% to -$7.0 million in 2023, then sank by 144392.13% to -$10.1 billion in 2024, then plunged by 150.73% to -$25.3 billion in 2025, then soared by 99.89% to -$26.9 million in 2026.
- Business Quant data shows BLTE's Income towards Parent Company at -$26.9 million in Q1 2026, -$25.3 billion in Q4 2025, and -$21.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.94 Mn |
| Dec 31, 2025 | -25.32 Bn |
| Sep 30, 2025 | -21.69 Bn |
| Jun 30, 2025 | -16.32 Bn |
| Mar 31, 2025 | -14.28 Mn |
| Dec 31, 2024 | -10.10 Bn |
| Sep 30, 2024 | -8.67 Bn |
| Jun 30, 2024 | -9.49 Bn |
| Mar 31, 2024 | -7.87 Bn |
| Dec 31, 2023 | -6.99 Mn |
| Sep 30, 2023 | -10.94 Mn |
| Jun 30, 2023 | -6.81 Bn |
| Mar 31, 2023 | -6.90 Bn |
| Dec 31, 2022 | -6.78 Mn |
| Sep 30, 2022 | -2.40 Bn |
| Jun 30, 2022 | -2.39 Bn |